Literature DB >> 8630585

Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.

D Walmrath1, T Schneider, R Schermuly, H Olschewski, F Grimminger, W Seeger.   

Abstract

Inhalation of NO and aerosolization of PGI2 have been suggested to achieve selective pulmonary vasodilation and improvement of arterial oxygenation in patients with ARDS. We directly compared these two modes of transbronchial vasodilator therapy in 16 ARDS patients mechanically ventilated (mean lung injury score [1] 2.75 +/- 0.05). Patients were randomized to receive either first NO and then PGI2, or vice versa. Each drug was individually titrated to find the maximum improvement of arterial oxygenation. Gas exchange variables, including data from the multiple inert gas elimination technique (MIGET), and hemodynamics under application of NO/PGI2 were compared with pre- and post-challenge values. NO (17.8 +/- 2.7 ppm) increased Pa O2/FI O2 from 115 +/- 12 to 144 +/- 15 mm Hg (p<0.01) and reduced the shunt-flow from 33.1 +/- 3.6 to 26.6 +/- 4.5% (p<0.05). Aerosolized PGI2 (7.5 +/- 2.5 ng/kg min) augmented Pa O2/FI O2 from 114 +/- 12 to 135 +/- 12 mm Hg (p<0.01), and decreased shunt from 33.5 +/- 3.8 to 26.0 +/- 3.9% (p<0.05). In 10 patients, both NO and PGI2 caused an increase in Pa O2/FI O2 by at least 10 mm Hg. Two further patients displayed an improvement of arterial oxygenation in response to either NO or PGI2. NO decreased mean pulmonary artery pressure from 34.8 +/- 2.2 to 33.0 +/- 1.8 mm Hg, and PGI2 from 35.0 +/- 2.2 to 31.9 +/- 1.7 mm Hg (p<0.05). We conclude that individually titrated doses of inhaled NO and aerosolized PGI2 effect selective pulmonary vasodilation and redistribute blood-flow from shunt-areas to well-ventilated regions with nearly identical efficacy profiles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630585     DOI: 10.1164/ajrccm.153.3.8630585

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  30 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  [Inhaled nitric oxide for the treatment of ARDS].

Authors:  H Lohbrunner; M Deja; T Busch; C D Spies; R Rossaint; U Kaisers
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

3.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

Review 4.  The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure.

Authors:  A T Dinh-Xuan; F Brunet; J F Dhainaut
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

Review 5.  Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS).

Authors:  Arash Afshari; Anders Bastholm Bille; Mikkel Allingstrup
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

Review 6.  Ventilatory strategies and supportive care in acute respiratory distress syndrome.

Authors:  Andrew M Luks
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

7.  [Aerosolized and intravenous prostacyclin during one-lung ventilation. Hemodynamic and pulmonary effects].

Authors:  M Bund; D Henzler; R Walz; R Rossaint; S Piepenbrock; R Kuhlen
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

8.  Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.

Authors:  Beena G Sood; Elizabeth J Dawe; Krishna Rao Maddipati; Monica Malian; Xinguang Chen; Robert Galli; Raja Rabah
Journal:  Pulm Pharmacol Ther       Date:  2008-02-06       Impact factor: 3.410

Review 9.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.